» Articles » PMID: 19793383

Matched Unrelated Donor Stem Cell Transplant in 131 Patients with Follicular Lymphoma: an Analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Abstract

Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the outcome of patients with FL treated with MUD-SCT included in the European Group for Blood and Marrow Transplantation registry. 131 patients treated with reduced-intensity conditioning (RIC, n = 87) or conventional myeloablative (CONV, n = 44) MUD-SCT between 2000 and 2005 were included. Median time from diagnosis to MUD-SCT was 47 months and the median number of previous therapeutic regimens was 4 (previous autograft: 47%). RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) was 24% and 30% at 100-d and 1-year, respectively. After a median follow-up of 36 months, 17% of the patients developed disease progression, the 3-year progression-free survival (PFS) being 47%. Three-year overall survival (OS) for the whole series was 51%. On multivariate analysis, RIC regimens were associated with at lower NRM and a significantly longer PFS and OS. This retrospective study demonstrated that MUD-SCT results, even in heavily pre-treated populations, in a meaningful PFS and OS.

Citing Articles

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.

Mei M, Palmer J, Tsai N, Simpson J, OHearn J, Stein A Clin Lymphoma Myeloma Leuk. 2023; 23(9):e268-e276.

PMID: 37301631 PMC: 10524945. DOI: 10.1016/j.clml.2023.05.011.


A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?.

Chung C Blood Lymphat Cancer. 2022; 12:99-106.

PMID: 35959380 PMC: 9359712. DOI: 10.2147/BLCTT.S282247.


CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.

Chavez J, Bachmeier C, Kharfan-Dabaja M Ther Adv Hematol. 2019; 10:2040620719841581.

PMID: 31019670 PMC: 6466472. DOI: 10.1177/2040620719841581.


Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Forero-Torres A, Ramchandren R, Yacoub A, Wertheim M, Edenfield W, Caimi P Blood. 2019; 133(16):1742-1752.

PMID: 30803990 PMC: 6543513. DOI: 10.1182/blood-2018-08-867499.


Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?.

Kharfan-Dabaja M, El-Jurdi N, Ayala E, Kanate A, Savani B, Hamadani M Bone Marrow Transplant. 2017; 52(11):1487-1494.

PMID: 28368373 DOI: 10.1038/bmt.2017.55.